Liberty Bioscience, LLC

Hepione Therapeutics Inc. is a biotech startup based in New York City, specializing in the development of monoclonal antibodies aimed at preventing opioid overdoses, particularly from fentanyl. Utilizing their proprietary VAST platform, the company generates high-affinity antibodies that can effectively neutralize the toxic effects of small molecules associated with opioid use disorders. Founded by a team of experienced scientists and business experts, Hepione is located within the BioLabs NYU Langone laboratories, part of a rapidly growing biotech cluster in Manhattan. The company is committed to addressing the ongoing U.S. overdose epidemic by partnering with leading pharmaceutical firms to tailor their innovative solutions to specific needs in the field. Generated from the website

Lauren Sciences LLC, based in New York, NY, is a pioneering company that addresses the significant challenge in treating central nervous system (CNS) diseases. Their breakthrough V-Smart Platform enables the delivery of therapeutic agents, including nucleic acids, antibodies, biologics, and small molecules, to the brain, overcoming the blood-brain barrier (BBB) non-invasively and with triple-targeted precision. With a robust pipeline of V-Smart Nanomedicines in development for various CNS indications such as ALS, PD, AD, Neuro-HIV, GBM, and Chronic Pain, Lauren Sciences aims to significantly improve patients' lives by providing access to therapeutic agents that were previously unavailable due to BBB limitations, pharmacokinetics, bioavailability, toxicity, invasive treatments, or the preference for oral administration.Generated from the website

SIGA Technologies applies microbial genomics to the design and development of novel products that prevent and treat infectious diseases, as well as defend against biological warfare agents. With technology platforms in both vaccines and antibiotics, the company s platform technologies include a vaccine delivery system that activates the immune system at the body s mucosal surfaces in order to prevent infection at the earliest possible stage, a surface protein expression system for the cost-effective production of proteins, biothreat rapid response therapeutics that can be rapidly designed on demand for any biological pathogen and virus counterstrike capability technology that can be used to develop safe and effective antivirals by targeting the proteinases which are encoded within all viruses. SIGA Technologies is headquartered in New York.